Management of Cancer using Photodynamic Therapy: Advancement and Applications

IF 0.4 Q4 ONCOLOGY
Deepika Yadav, Pramod Sharma, Prem Mishra, Rishabha Malviya
{"title":"Management of Cancer using Photodynamic Therapy: Advancement and Applications","authors":"Deepika Yadav, Pramod Sharma, Prem Mishra, Rishabha Malviya","doi":"10.2174/0115733947239258231003091058","DOIUrl":null,"url":null,"abstract":"Photosensitizers (PS) are effective in treating a wide range of tumours using the timetested technique of photodynamic therapy (PDT). Light has been employed for centuries as a curative modality due to its efficacy. Since the effects of using certain dyes in conjunction with light irradiation were first proven around the turn of the 20th century, new PDT methods have been created. Current research focuses mostly on methods to lessen or eliminate unwanted side effects and enhance the drug's pharmacokinetic qualities. The FDA's decision to approve PDT as the first drug/device combo is not surprising, given the widespread curiosity and volume of published material on the subject. In PDT, light energy is combined with a PS to destroy tumour cells after its activation by light. In comparison to chemotherapy and/or radiation treatment, PDT often has fewer adverse effects and is safer. Several different PSs may be used to diagnose tumours, in addition to their therapeutic use. Photodynamic diagnostics (PDD) is the term used to describe methods like these. In this review, we present a high-level introduction to the diagnostic and therapeutic uses of PDT in cancer. The need of developing predictors to determine the response to therapy will be explored in relation to the assessment of PDT therapeutic effectiveness in the clinic. The use of PDT to treat different tumours will also be shown through case studies. The potential of combining PDT with other forms of treatment, such as chemotherapy, radiation, surgery, and immunotherapy, to increase efficacy against tumours will also be highlighted. Results from PDT alone may not be as good as those from PDT combined with other therapies. It's also possible that lower dosages used in combination therapy will have fewer adverse effects and provide better outcomes than each individual treatment would. It is possible that the therapeutic uses of PDT might be broadened by a greater knowledge of the efficacy of PDT in a combination context in the clinic, as well as the optimisation of such complicated multimodal therapies.","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"20 1","pages":"0"},"PeriodicalIF":0.4000,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cancer Therapy Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115733947239258231003091058","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Photosensitizers (PS) are effective in treating a wide range of tumours using the timetested technique of photodynamic therapy (PDT). Light has been employed for centuries as a curative modality due to its efficacy. Since the effects of using certain dyes in conjunction with light irradiation were first proven around the turn of the 20th century, new PDT methods have been created. Current research focuses mostly on methods to lessen or eliminate unwanted side effects and enhance the drug's pharmacokinetic qualities. The FDA's decision to approve PDT as the first drug/device combo is not surprising, given the widespread curiosity and volume of published material on the subject. In PDT, light energy is combined with a PS to destroy tumour cells after its activation by light. In comparison to chemotherapy and/or radiation treatment, PDT often has fewer adverse effects and is safer. Several different PSs may be used to diagnose tumours, in addition to their therapeutic use. Photodynamic diagnostics (PDD) is the term used to describe methods like these. In this review, we present a high-level introduction to the diagnostic and therapeutic uses of PDT in cancer. The need of developing predictors to determine the response to therapy will be explored in relation to the assessment of PDT therapeutic effectiveness in the clinic. The use of PDT to treat different tumours will also be shown through case studies. The potential of combining PDT with other forms of treatment, such as chemotherapy, radiation, surgery, and immunotherapy, to increase efficacy against tumours will also be highlighted. Results from PDT alone may not be as good as those from PDT combined with other therapies. It's also possible that lower dosages used in combination therapy will have fewer adverse effects and provide better outcomes than each individual treatment would. It is possible that the therapeutic uses of PDT might be broadened by a greater knowledge of the efficacy of PDT in a combination context in the clinic, as well as the optimisation of such complicated multimodal therapies.
利用光动力疗法管理癌症:进展与应用
光敏剂(PS)在使用经过时间考验的光动力疗法(PDT)技术治疗多种肿瘤方面是有效的。由于其疗效,光作为一种治疗方式已经被使用了几个世纪。由于使用某些染料与光照射的效果在20世纪初首次被证明,新的PDT方法已经被创造出来。目前的研究主要集中在减少或消除不良副作用和提高药物的药代动力学质量的方法上。FDA决定批准PDT作为第一个药物/设备组合并不令人惊讶,考虑到广泛的好奇心和关于该主题的出版材料的数量。在PDT中,光能与PS结合,在被光激活后摧毁肿瘤细胞。与化疗和/或放疗相比,PDT通常副作用更少,也更安全。几种不同的ps除了用于治疗外,还可用于诊断肿瘤。光动力诊断(PDD)是用来描述这些方法的术语。在这篇综述中,我们介绍了PDT在癌症诊断和治疗中的应用。需要发展的预测因素,以确定对治疗的反应,将探讨在临床评估PDT治疗效果。使用PDT治疗不同的肿瘤也将通过案例研究来展示。将PDT与其他形式的治疗,如化疗、放疗、手术和免疫治疗相结合,以提高对肿瘤的疗效的潜力也将得到强调。PDT单独治疗的结果可能不如PDT联合其他治疗的结果好。也有可能,在联合治疗中使用较低的剂量会产生较少的副作用,并提供比单独治疗更好的结果。有可能,PDT的治疗用途可能会扩大,通过更多的知识,PDT在临床的联合背景下的疗效,以及这种复杂的多模式治疗的优化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
50
期刊介绍: Current Cancer Therapy Reviews publishes frontier reviews on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信